Trial · NCT03713294

Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma

NCT03713294, Phase 2, Completed, Mayo Clinic; results first posted 2025-06-24

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma. Trials, record NCT03713294. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03713294

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma
NCT number: NCT03713294
Status: Completed
Phases: Phase 2
Enrollment: 37 participants, actual
Lead sponsor: Mayo Clinic
Conditions: Refractory Plasma Cell Myeloma
Interventions: Dexamethasone, Elotuzumab, Pomalidomide
First posted: 2018-10-19
Last updated: 2025-06-24
Results first posted: 2025-06-24

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Overall Response Rate	3 years	Overall response rate (ORR) defined as a partial response (PR), very good partial response (VGPR), complete response (CR) or stringent CR (sCR). CR and sCR are defined in Outcome 2. VGPR requires: serum and urine M-protein detectable by immunofixation but not on electrophoresis OR \>= 90% reduction in serum M-protein and urine M-protein \<100 mg/24 h. If the only measurable disease is FLC, a \>90% reduction in the difference between involved and uninvolved FLC levels. PR requires: if present at baseline, \>= 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>= 90% or to \<200 mg/24hrs. If the only measurable disease is FLC, a ≥50% reduction in the difference between involved and uninvolved FLC levels. If the only measurable disease is BM, a ≥ 50% reduction in BM PCs (provided the baseline PCs was ≥ 30%). If present at baseline, ≥ 50% reduction in the size (SPD) of soft tissue plasmacytomas.
Secondary	Percentage of Patients Achieving CR	3 years	Will be estimated by the number of patients who achieve a sCR or CR divided by the total number of evaluable patients. Complete Response (CR) is defined by all of the following: negative immunofixation of serum and urine; disappearance of any soft tissue plasmacytoma; \<5% PCs in bone marrow; and if the only measurable disease is Free Light Chain (FLC), a normal FLC ratio. Stringent Complete Response (sCR) is defined as CR plus normal FLC ratio and absence of clonal circulating plasma cells (PCs) immunohistochemistry or 2- to 4- color flow cytometry.
Secondary	Progression-free Survival (PFS)	3 years	PFS is defined as the time from registration to time of disease progression or death due to any cause.
Secondary	Count of Patients That Experienced a Grade 3 or Greater Adverse Events	37 months	The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. The table of these events is located in the adverse events section of this report.
Secondary	Overall Survival (OS)	62 months	OS is defined as the time from registration to death due to any cause.

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Overall Response Rate	3 years	proportion of participants	NUMBER
SECONDARY	Percentage of Patients Achieving CR	3 years	percentage of patients who achieve CR	NUMBER
SECONDARY	Progression-free Survival (PFS)	3 years	months	MEDIAN
SECONDARY	Count of Patients That Experienced a Grade 3 or Greater Adverse Events	37 months	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Overall Survival (OS)	62 months	Months	MEDIAN

Source ClinicalTrials.gov

Results by group5

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Overall Response Rate	Treatment	0.35		proportion of participants
Percentage of Patients Achieving CR	Treatment	0		percentage of patients who achieve CR
Progression-free Survival (PFS)	Treatment	3.7	95% Confidence Interval 2.9 to 11.1	months
Count of Patients That Experienced a Grade 3 or Greater Adverse Events	Treatment	27		Participants
Overall Survival (OS)	Treatment	56.7	95% Confidence Interval 27.2 to NA	Months

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Treatment	37
Overall Study	COMPLETED	Treatment	37
Overall Study	NOT COMPLETED	Treatment	0

Source ClinicalTrials.gov

Adverse events55

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anemia	Blood and lymphatic system disorders	Treatment	33	37	264
other	Blood and lymph sys disorders - Oth Spec	Blood and lymphatic system disorders	Treatment	2	37	2
other	Endocrine disorders - Other, specify	Endocrine disorders	Treatment	1	37	1
other	Constipation	Gastrointestinal disorders	Treatment	1	37	1
other	Gastrointestinal pain	Gastrointestinal disorders	Treatment	1	37	1
other	Edema face	General disorders	Treatment	1	37	1
other	Fatigue	General disorders	Treatment	27	37	247
other	Gen disord and admin site conds-Oth spec	General disorders	Treatment	1	37	1
other	Allergic reaction	Immune system disorders	Treatment	1	37	1
other	Lung infection	Infections and infestations	Treatment	1	37	1

1 to 10 of 55Source ClinicalTrials.gov

See all 55 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Treatment	18	37
Total, other adverse events	Treatment	37	37
Total, serious adverse events	Treatment	12	37

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
P30CA015083	Mayo Clinic Comprehensive Cancer Center Support Grant	WILLMAN, CHERYL LYNN	MAYO CLINIC ROCHESTER	NATIONAL CANCER INSTITUTE	1985 to 2025

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03713294

GET https://conductscience.org/api/trials/v1/NCT03713294/events?page=2

API reference For AI assistants